Toxicity after prolonged (more than four weeks) administration of intravenous colistin

Abstract number: 1134_02_275

Falagas M., Rizos M., Bliziotis I., Rellos K., Kasiakou S., Michalopoulos A.


To study the toxicity of prolonged intravenous administration of colistin


Observational study of retrospective cohort.


‘Henry Dunant’ Hospital, a 450-bed tertiary care centre in Athens, Greece.


Patients who received intravenous colistin for more than 4 weeks for the treatment of multidrug resistant Gram-negative infections.

Main outcome measures:

Serum creatinine, blood urea, liver function tests, symptoms and signs of neurotoxicity.


We present our experience with the use of 19 courses of prolonged intravenous colistin [mean duration of administration (±SD) 43.4 (±14.6) days, mean daily dosage (±SD) 4.4 (±2.1) million IU, mean cumulative dosage (±SD) 190.4 (±91.0) million IU] in 17 patients. The median creatinine value increased by 0.25 mg/dl during the treatment compared to the baseline (p < 0.001) but returned close to the baseline at the end of treatment (higher by 0.1 mg/dl, p = 0.67). No apnea or other evidence of neuromuscular blockade was noted in any of these patients who received prolonged treatment with colistin.


No serious toxicity was observed in patients who received prolonged intravenous colistin. Colistin should be considered as a therapeutic option in patients with infections due to multidrug resistant Gram-negative bacteria.

Session Details

Date: 01/08/2007
Time: 00:00-00:00
Session name: XXIst ISTH Congress
Location: Oxford, UK
Presentation type:
Back to top